Advanced search    

Search: authors:"J. D. Adachi"

9 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

The impact of GI events on persistence and adherence to osteoporosis treatment: 3-, 6-, and 12-month findings in the MUSIC-OS study

Summary The goal of this multinational, prospective, observational study was to examine the relationship between gastrointestinal (GI) events and self-reported levels of medication adherence and persistence in postmenopausal women. A total of 73.9% of patients remained on their osteoporosis (OP) therapy at month 12, although the presence of a GI event at baseline, month 3, and...

Association of gastrointestinal events with quality of life and treatment satisfaction in osteoporosis patients: results from the Medication Use Patterns, Treatment Satisfaction, and Inadequate Control of Osteoporosis Study (MUSIC OS)

Summary The purpose of this study was to assess the association of GI events with HRQoL and treatment satisfaction. The effect of baseline GI events persisted through 1 year of follow-up, as indicated by lower EQ-5D, OPAQ-SV, and treatment satisfaction scores among patients with vs without baseline GI events. The presence of GI events is an independent predictor of decreased...

Gastrointestinal symptoms and association with medication use patterns, adherence, treatment satisfaction, quality of life, and resource use in osteoporosis: baseline results of the MUSIC-OS study

own stock in the company. J. D. Adachi has received grant support and speaker honorarium from Actavis, Amgen, Eli Lilly, Merck & Co., Inc., and Novartis and is a consultant for Amgen, Eli Lilly, and

Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years

Summary Limited data exist on the efficacy of long-term therapies for osteoporosis. In osteoporotic postmenopausal women receiving denosumab for 7 years, nonvertebral fracture rates significantly decreased in years 4–7 versus years 1–3. This is the first demonstration of a further benefit on fracture outcomes with long-term therapy for osteoporosis. Introduction This study aimed...

The burden of illness of osteoporosis in Canada

Summary To update the 1993 burden of illness of osteoporosis in Canada, administrative and community data were used to calculate the 2010 costs of osteoporosis at $2.3 billion in Canada or 1.3% of Canada’s healthcare expenditures. Prevention of fractures in high-risk individuals is key to decrease the financial burden of osteoporosis. Introduction Since the 1996 publication of...

A reappraisal of generic bisphosphonates in osteoporosis

, University of Southampton , Southampton, UK 4 R. Rizzoli University Hospitals and Faculty of Medicine of Geneva , Geneva, Switzerland 5 J. D. Adachi St Joseph's Healthcare and McMaster University , Hamilton

Failure to perceive increased risk of fracture in women 55 years and older: the Global Longitudinal Study of Osteoporosis in Women (GLOW)

Leuven University Center for Metabolic Bone Diseases, Division of Geriatric Medicine, Katholieke Universiteit Leuven , Leuven, Belgium 2 J. D. Adachi St. Joseph's Hospital, McMaster University , Hamilton

The Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design

Rheumatology, University of Verona , Ospedale, Verona, Valeggio, Italy 2 J. D. Adachi St. Joseph's Hospital, McMaster University , Hamilton, Ontario, Canada 3 S. L. Greenspan University of Pittsburgh